Trevena, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
  • Pipeline
    • Overview
    • TRV250
    • TRV734
    • TRV045
    • TRV027
  • Products
    • OLINVYK™ (oliceridine) injection
  • Medical Affairs
    • Investigator-Initiated Trials
    • Contact Medical Information
  • Publications
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Financial Info
    • Stock Info
    • Resources
    • Governance
  • Careers
  • Contact

Press Releases

Investors

Investors

  • Overview
  • Press Releases
  • Events & Presentations
    • Presentations
    • IR Calendar
  • Financial Info
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Stock Info
    • Quote
    • Analyst Coverage
  • Resources
    • Email Alerts
    • Contacts
    • FAQ
  • Governance
    • Overview
    • Management Team
    • Board of Directors
    • Governance Documents

Trevena to Present at the 21st Annual BIO CEO & Investor Conference

Feb 05, 2019 6:58pm EST

Trevena Announces $10 Million Registered Direct Offering of Common Stock

Jan 30, 2019 7:00am EST

Trevena Announces Receipt of Type A Meeting Minutes and Provides Regulatory Update for Oliceridine

Jan 28, 2019 7:00am EST

National Institute on Drug Abuse Presents Data on Trevena’s TRV734 at the 57th Annual Meeting of the American College of Neuropsychopharmacology

Dec 13, 2018 4:01pm EST

Trevena Promotes Robert T. Yoder to Senior Vice President and Chief Business Officer

Dec 10, 2018 7:00am EST

Trevena Reports Third Quarter 2018 Financial Results and Announces Workforce Restructuring

Nov 08, 2018 7:00am EST

Trevena Receives Complete Response Letter for Oliceridine from FDA

Nov 02, 2018 1:42pm EDT

Trevena to Present Phase 3, Open-Label Safety Study of Oliceridine at the American Society of Anesthesiologists Annual Meeting

Oct 12, 2018 4:01pm EDT

Trevena Announces Oliceridine FDA Advisory Committee Meeting Outcome

Oct 11, 2018 5:04pm EDT

Trevena Stock Trading Halted; FDA Advisory Committee to Review Oliceridine for the Treatment of Moderate to Severe Acute Pain

Oct 11, 2018 7:00am EDT
RSS
  • Prev
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...25
    Next
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed
    © 2021 Trevena, Inc. All Rights Reserved.
    Privacy Policy Terms of Use Disclaimer Sitemap